CIK 0001636282 · Large accelerated filer
Spyre Therapeutics, Inc.
Sign in to watch- Ticker
- SYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464312787
- Phone
- 6176515940
- Business address
- 221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aeglea BioTherapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,349,597
- in 6 filings, $12.3M under 10b5-1 plans
Net −$12,349,597. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-11-24 | Albers Jeffrey W. Director | Conversion | +34,360 | 34,360 | ||
| 2023-11-24 | Albers Jeffrey W. Director | Conversion · Series A Preferred Stock | −859 | 0 | ||
| 2023-11-24 | Fairmount Funds Management LLC Director | Conversion | +3,435,480 | 3,435,480 | ||
| 2023-11-24 | Fairmount Funds Management LLC Director | Conversion · Series A Preferred Stock | −85,887 | 0 | ||
| 2023-11-24 | Turtle Cameron Chief Executive Officer | Conversion | +723,440 | 746,507 | ||
| 2023-11-24 | Turtle Cameron Chief Executive Officer | Conversion · Series A Preferred Stock | −18,086 | 0 | ||
| 2023-11-22 | Albers Jeffrey W. Director | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2023-11-22 | Albers Jeffrey W. Director | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2023-11-22 | Stelzer Laurie Director | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2023-11-22 | Turtle Cameron Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +374,000 | 374,000 | ||
| 2023-09-01 | King-Jones Heidy See Remarks | Grant or award · Stock Option (Right to Buy) | +13,495,255 | 13,495,255 | ||
| 2023-09-01 | Burrows Scott L Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +10,121,441 | 10,121,441 | ||
| 2023-06-22 | Alspaugh Jonathan President and CFO | Grant or award · Employee Stock Option (right to buy) | +19,787,969 | 19,787,969 | ||
| 2023-06-22 | Cox Russell J. Director | Grant or award · Stock Option (right to buy) | +1,950,000 | 1,950,000 | ||
| 2023-06-22 | Magovcevic-Liebisch Ivana Director | Grant or award · Stock Option (right to buy) | +1,950,000 | 1,950,000 | ||
| 2023-06-22 | Smith Hunter C Director | Grant or award · Stock Option (right to buy) | +1,950,000 | 1,950,000 | ||
| 2023-06-22 | Lawton Alison Frances Director | Grant or award · Stock Option (right to buy) | +1,950,000 | 1,950,000 | ||
| 2023-02-23 | Neuman Linda L Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +550,000 | 550,000 | ||
| 2023-02-23 | Kastenmayer James Paul General Counsel | Grant or award · Employee Stock Option (right to buy) | +500,000 | 500,000 | ||
| 2023-02-23 | Hanley Jr. Michael Conick Chief Business Officer | Grant or award · Employee Stock Option (right to buy) | +500,000 | 500,000 |
Page 10 of 11 · 213 trades